mAb Development

Jun 01, 2017
BioPharm International
An increase in biologics raises awareness of particle generation and its role in negative patient outcomes.
May 05, 2017
By BioPharm International Editors
Operated by BioOutsource, Sartorius’ subsidiary, the Glasgow, UK-based service center will offer physicochemical properties and structural attributes testing and allow clients to perform structural and functional analyses in parallel.
May 01, 2017
BioPharm International
The unique structures of fusion proteins lead to expression, heterogeneity, and stability issues.
Apr 01, 2017
BioPharm International
Including next-gen antibodies in pharma pipelines is considered essential for future success.
Mar 29, 2017
The mAb is the first approved treatment that targets the progressive form of the disease.
Mar 27, 2017
By BioPharm International Editors
The Basel office will house the clinical development team and other functions to progress the company’s lead compound emapalumab.
Feb 27, 2017
By BioPharm International Editors
Sanofi and Lonza formed a joint venture to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Feb 22, 2017
By BioPharm International Editors
FDA granted inotuzumab ozogamicin priority review and accepted its BLA for filing.
Feb 14, 2017
Evaluate and BioPharm International highlight the antibody-based therapeutics that may have 2017 launch dates in the United States.
Feb 13, 2017
EvaluatePharma and BioPharm International highlight the antibody-based therapeutics that may gain United States Regulatory approval in 2017.
native1_300x100
lorem ipsum